Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 83 clinical trials
Staggered Chemo-Immunotherapy With Durvalumab MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC

This is a Phase II, open label, randomized study of durvalumab in combination with pemetrexed and carboplatin in eligible adult patients with locally advanced or metastatic non-small cell lung cancer. The study will focus on the efficacy of two alternative staggered dosing regimens.

measurable disease
neutrophil count
gilbert's syndrome
  • 24 Jan, 2021
  • 1 location
Endostar/PD-1 Inhibitors Combined With PP for Advanced NSCLC

A Controlled Clinical Study of Endostar/PD-1 Inhibitors Combined With chemotherapy(Carboplatin-Pemetrexed) as First-line Treatment for Advanced Non-squamous Cell Lung Cancer With Negative Driving Gene

  • 23 Jan, 2021
  • 1 location
Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003)

The study for innovative strategies is warranted in the treatment of advanced non-squamous NSCLC with epidermal growth factor receptor wild-type or unknown mutation status because the outcomes

  • 23 Jan, 2021
  • 2 locations
A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations

-IV Non-squamous non-small-cell lung cancer (NSCLC) harboring an activating epidermal growth factor receptor (EGFR) mutation (Del19 and L858R). Safety and tolerability of Apatinib in combination with

  • 21 Jan, 2021
Durvalumab in Combination With Chemotherapy in Virus-infected Patients With Non-small Cell Lung Cancer

weeks), followed by durvalumab (with or without pemetrexed for non-squamous NSCLC) maintenance therapy. We hypothesized that Durvalumab in combination with standard chemotherapy is safe and effective

  • 26 Jan, 2021
  • 2 locations
Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC)

This is a phase II clinical trial aimed at evaluating the efficacy of PD-L1 inhibition with atezolizumab in advanced squamous and non-squamous NSCLC patients previously treated with anti-PD-1

  • 26 Jan, 2021
  • 2 locations
An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR a HER2 or a HER3 Mutation

the first stage and an additional 19 in the second stage (maximum total 87 patients) Indication : cancers harbouring an EGFR mutation(excluding non-squamous non- small cell lung cancer, a

  • 22 Jan, 2021
  • 5 locations
A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors.

This is an open-label, multicenter, non-randomized Phase 1b clinical trial for patients with histologically or cytologically confirmed locally advanced or metastatic tumors including non-squamous or squamous NSCLC, RCC, OC, or melanoma.

  • 08 May, 2021
  • 16 locations
A Safety and Efficacy Study of TAK-981 Plus Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

The purpose of this study is to determine the safety and tolerability of TAK-981 in combination with pembrolizumab in participants with select solid tumor indications and to establish the recommended phase 2 dose (RP2D) during Phase 1b of study and to evaluate the preliminary efficacy of TAK-981 at the RP2D …

  • 26 Jan, 2021
  • 9 locations
SAR408701 in Combination With Pembrolizumab and Pembrolizumab Alone in Patients With Non-squamous Non-small Cell Lung Cancer (NSQ NSCLC)

Primary Objectives: Part A - Part 1 (safety run-in): To assess the tolerability and to confirm the recommended dose of SAR408701 in combination with pembrolizumab in the NSQ NSCLC population Part A - Part 2: To assess the antitumor activity of SAR408701 in combination with pembrolizumab and pembrolizumab single agent …

  • 23 Apr, 2021
  • 20 locations